trending Market Intelligence /marketintelligence/en/news-insights/trending/9pF-jkf2WWuIdIsILDcjwA2 content esgSubNav
In This List

U.K.'s Nemaura Medical plans public offering to fund glucose monitor study

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


U.K.'s Nemaura Medical plans public offering to fund glucose monitor study

Nemaura Medical Inc. is planning a registered public offering of its common stock and warrants.

The company plans to use the proceeds for a U.S. Food and Drug Administration clinical trial of its noninvasive glucose monitor sugarBEAT. Proceeds will also be used to launch the product in Europe and to develop a second generation of sugarBEAT.

Dawson James Securities Inc. is acting as the sole placement agent regarding the offering.

Further details, including the number of shares to be offered and financial information, were not disclosed in Nemaura's Dec. 17 press release.

Loughborough, U.K.-based Nemaura is a medical technology company that develops specialty medical devices.